- Home
- OMCL vs ANAB Comparison
OMCL vs ANAB Comparison
Compare OMCL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | ANAB |
|---|---|---|
| Founded | 1992 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | OMCL | ANAB |
|---|---|---|
| Price | $35.60 | $48.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $57.43 | ★ $87.25 |
| AVG Volume (30 Days) | ★ 566.1K | 395.2K |
| Earning Date | 10-29-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $787,309,000.00 | $234,603,000.00 |
| Revenue This Year | $3.69 | N/A |
| Revenue Next Year | $0.92 | $69.42 |
| P/E Ratio | $37.09 | ★ N/A |
| Revenue Growth | 9.93 | ★ 157.01 |
| 52 Week Low | $31.75 | $32.90 |
| 52 Week High | $51.84 | $73.30 |
Technical Indicators
Market Signals| Indicator | OMCL | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 48.97 |
| Support Level | $32.11 | $44.25 |
| Resistance Level | $36.63 | $51.70 |
| Average True Range (ATR) | 1.83 | 1.80 |
| MACD | -0.10 | 0.15 |
| Stochastic Oscillator | 12.88 | 50.32 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).